Drug Trial Radar · NCT06334133
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jun 14, 2024
Primary completion
Apr 2027
Study completion May 2027
Sponsor
- Lead sponsor
- vTv TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
Conditions
- Diabetes Mellitus, Type 1
Interventions
Cadisegliatin 800 mg QDDrug
Cadisegliatin is an orally bioavailable small-molecule glucokinase activator; adjunctive therapy to insulin.
Cadisegliatin 800 mg BIDDrug
Cadisegliatin is an orally bioavailable small-molecule glucokinase activator; adjunctive therapy to insulin.
PlaceboDrug
Placebo (insulin alone)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in incidence of Level 2 or Level 3 hypoglycemiaTime frame: 26 weeks
Locations
48 sites in 2 countries. Site status is shown where the registry gives one.
Scottsdale Clinical Trials
Scottsdale, Arizona
Baptist Health Center for Clinical Research
Little Rock, Arkansas
John Muir Physician Network Clinical Research Center
Concord, California
Amicis Research Center
Granada Hills, California
AME Clinical Research
Huntington Beach, California
Scripps Whittier Diabetes Institute
La Jolla, California
IMAX Clinical Trials
La Palma, California
Paradigm Clinical Research - Modesto
Modesto, California
Paradigm Clinical Research Centers LLC
San Diego, California
Acclaim Clinical Research
San Diego, California
The Lundquist Institute
Torrance, California
Focus Clinical Research
West Hills, California
Denver Endocrinology Diabetes and Thyroid Center
Englewood, Colorado
BayCare Health Systems
Clearwater, Florida
Metabolic Research Institute, Inc
West Palm Beach, Florida
Atlanta Diabetes Associates
Atlanta, Georgia
Centricity Research - Columbus
Columbus, Georgia
The Jones Center Clinical Research, LLC
Macon, Georgia
DM Clinical Research
Indianapolis, Indiana
Accellacare - McFarland
Ames, Iowa
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa
Johnson County Clin-Trials, LLC
Lenexa, Kansas
MedStar Good Samaritan Hospital
Baltimore, Maryland
Massachusetts General Hospital Diabetes Research Center
Boston, Massachusetts
Profound Research LLC
Farmington Hills, Michigan
Excel Clinical Research
Las Vegas, Nevada
Palm Research Center
Las Vegas, Nevada
Vector Clinical Trials
Reno, Nevada
AMC Community Endocrinology
Albany, New York
Jacobi Medical Center
The Bronx, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Javarra Inc.
Charlotte, North Carolina
Physician's East PA
Greenville, North Carolina
Centricity Research Morehead City Multispecialty
Morehead City, North Carolina
Diabetes & Endocrinology Associates of Stark County, Inc
Canton, Ohio
Velocity Clinical Research
Medford, Oregon
University of Pennsylvania Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania
Circle Clinical Research
Sioux Falls, South Dakota
Texas Diabetes and Endocrinology, P.A
Austin, Texas
Velocity Clinical Research - Dallas
Dallas, Texas
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.